Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
19 November 2020Website:
http://www.olema.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 22 min agoDividend
Analysts recommendations
Institutional Ownership
OLMA Latest News
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that its management team will participate in the following upcoming investor conferences:
Olema Pharmaceuticals, Inc. ("Olema", "Olema Oncology", Nasdaq: OLMA), a company developing targeted therapies for women's cancers, shared that its management team will be present at upcoming investor conferences.
SAN FRANCISCO, April 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel on “Breast Cancer – Shifting an Entrenched Paradigm” at the 2024 CG Horizons in Oncology Virtual Conference on Monday, April 15, 2024, at 2:00 p.m. ET.
SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company will participate in the following upcoming investor conferences:
Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with palbociclib, and the OPERA-01 Phase 3 clinical trial in progress will be presented on Dec. 7, 2023
Today, we revisit Olema Pharmaceuticals, Inc. for the first time in two years. Olema is a clinical-stage biotech company focused on developing therapies for women's cancers. Their primary product candidate, palazestrant, has been granted FDA Fast Track designation for the treatment of metastatic breast cancer. Palazestrant is advancing in development both as a potential monotherapy and as part of potential combination therapies.
Olema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication.
SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company will present at the following upcoming investor conferences in November:
Olema Pharmaceuticals, Inc. (OLMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Olema Pharmaceuticals, Inc. (OLMA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
What type of business is Olema Pharmaceuticals?
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
What sector is Olema Pharmaceuticals in?
Olema Pharmaceuticals is in the Healthcare sector
What industry is Olema Pharmaceuticals in?
Olema Pharmaceuticals is in the Biotechnology industry
What country is Olema Pharmaceuticals from?
Olema Pharmaceuticals is headquartered in United States
When did Olema Pharmaceuticals go public?
Olema Pharmaceuticals initial public offering (IPO) was on 19 November 2020
What is Olema Pharmaceuticals website?
https://www.olema.com
Is Olema Pharmaceuticals in the S&P 500?
No, Olema Pharmaceuticals is not included in the S&P 500 index
Is Olema Pharmaceuticals in the NASDAQ 100?
No, Olema Pharmaceuticals is not included in the NASDAQ 100 index
Is Olema Pharmaceuticals in the Dow Jones?
No, Olema Pharmaceuticals is not included in the Dow Jones index
When does Olema Pharmaceuticals report earnings?
The next expected earnings date for Olema Pharmaceuticals is 08 August 2024